3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

Impact · against what's priced in

The article provides concrete evidence of a financial turnaround for Teladoc Health and market expansion strategies for DexCom, while identifying a speculative tailwind for Ollie's Bargain Outlet. Because these specific catalysts—debt reduction, AI-driven margin growth, and OTC glucose monitoring—are not yet fully absorbed into valuation models, they represent actionable upside.

DXCM+0.40: No priced-in read yet

3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

What matters in this story

Here's Every Monthly Check These 3 Dividend ETFs Paid Over the Past Year

3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

What matters in this story

Here's Every Monthly Check These 3 Dividend ETFs Paid Over the Past Year

How each ticker is affected

Connected tickers

Track these names every morning.

Teleflex Q3 Earnings Call Highlights

AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy

Perrigo Q3 Earnings Call Highlights

McKesson Q2 Earnings Call Highlights

3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

What matters in this story

Next reads from the same story arc

Here's Every Monthly Check These 3 Dividend ETFs Paid Over the Past Year

3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

What matters in this story

Next reads from the same story arc

Here's Every Monthly Check These 3 Dividend ETFs Paid Over the Past Year

How each ticker is affected

Connected tickers

Track these names every morning.

Teleflex Q3 Earnings Call Highlights

AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy

Perrigo Q3 Earnings Call Highlights

McKesson Q2 Earnings Call Highlights